Home Cart Sign in  
Chemical Structure| 141699-58-3 Chemical Structure| 141699-58-3

Structure of 141699-58-3

Chemical Structure| 141699-58-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 141699-58-3 ]

CAS No. :141699-58-3
Formula : C9H17NO5S
M.W : 251.30
SMILES Code : CC(C)(C)OC(=O)N1CC(C1)OS(C)(=O)=O
MDL No. :MFCD05664832
InChI Key :XXBDTKYKFFIAEY-UHFFFAOYSA-N
Pubchem ID :10753243

Safety of [ 141699-58-3 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H317-H319
Precautionary Statements:P280-P305+P351+P338

Computational Chemistry of [ 141699-58-3 ] Show Less

Physicochemical Properties

Num. heavy atoms 16
Num. arom. heavy atoms 0
Fraction Csp3 0.89
Num. rotatable bonds 5
Num. H-bond acceptors 5.0
Num. H-bond donors 0.0
Molar Refractivity 61.83
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

81.29 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

2.56
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

0.37
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

1.28
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

0.34
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-0.53
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

0.8

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-1.3
Solubility 12.6 mg/ml ; 0.05 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-1.64
Solubility 5.73 mg/ml ; 0.0228 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-0.77
Solubility 42.3 mg/ml ; 0.168 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

No
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

Yes
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-7.57 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

0.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

1.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<0.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

2.82

Application In Synthesis of [ 141699-58-3 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 141699-58-3 ]

[ 141699-58-3 ] Synthesis Path-Downstream   1~3

  • 1
  • [ 269410-08-4 ]
  • [ 141699-58-3 ]
  • [ 877399-35-4 ]
YieldReaction ConditionsOperation in experiment
NaH (60% in mineral oil, 222 mg, 5.6 mmol) is added portionwise to a stirred solution of A- (4,4,5,5-Tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-1H-pyrazole (1.10 g, 5.56 mmol) in DMF (20 ml). The resulting mixture is stirred for 1 h at O0C and then allowed to warn to RT. A solution of 3-Methanesulfonyloxy-azetidine-i-carboxylic acid tert-butyl ester (as obtained in <n="61"/>preparation 80, 1.39 g, 5.56 mmol) in DMF (3 ml) is then added dropwise. After complete addition, the reaction mixture is heated at 95C for 5h. The reaction is quenched with water and extracted with EtOAc several times. The combined organic layers are washed with brine, dried over Na2SO4, filtered and the filtrate is concentrated in vacuo. The residue is purified by chromatography on a 40 g silica gel column on a Combiflash Companion (Isco Inc.) apparatus ( gradient CH2CI2: TBDME from 1 :0 => 0:1 ) to afford the title compound as a colorless foam, R1 = 1.200 min (Acquity UPLC BEH C18, 2.1x50mm, 1.7 micron, detection 215nM, 0.1 min 2% CH3CN in H2O , 2% to 100% CH3CN in H2O in 1.5min, 0.4 min 100% CH3CN + 0.1% TFA, flow rate 1.Oml/min); MS: 350 (M+1)+ .
Stage 146.3 <n="119"/>; 3-[4-(4,4,5,5-Tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-pyrazol-1-yl]-azetidine-1-carboxylic acid tert-butyl ester; The title compound was prepared as described in published patent application WO 2008148867: To a solution of 1-BOC-3-hydroxyazetidine (1.0 g, 5.77 mmol), 4-dimethylaminopyridine (7 mg, 0.058 mmol) and triethylamine (0.880 ml_, 6.35 mmol) in DCM (15 mL) cooled at 0 0C was added dropwise methanesulfonyl chloride (0.45 mL, 5.77 mmol). The RM was stirred 18 h at rt, diluted with DCM, washed with a solution of saturated NaHCO3 and brine. The organic layer was dried over Na2SO4, filtered and the solvent was removed under reduced pressure. 3-Methanesulfonyloxy-azetidine-i-carboxylic acid tert-butyl ester obtained as an oil was used directly in the next step.To a solution of 4-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1H-pyrazole (1.4 g 5.57 mmol) in DMF (20 mL) stirred at 0 0C was added sodium hydride (55 % in oil, 0.243 g, 5.57 mmol). After addition the mixture was stirred 1 h at rt, a solution of the above obtained 3- methanesulfonyloxy-azetidine-1-carboxylic acid tert-butyl ester (1.4 g, 5.57 mmol) in DMF (3 mL) was added. The RM was stirred 30 min at rt, and then 3 h at 95 0C. After cooling at rt the mixture was poured in ice water and extracted with EtOAc. The combined organic phases were washed with a solution of saturated NaHCO3 and brine. The organic layer was dried over Na2SO4, filtered and the solvent was removed under reduced pressure. The residue was purified by flash chromatography (with heptane and EtOAc as eluants) to afford the title compound as an oil (tR 4.33 min (conditions 3), MH+ = 350.1)
With caesium carbonate; In N,N-dimethyl-formamide; at 100℃; for 14h;Inert atmosphere; A solution of 4-(4.4.5.5-tctramcthyl- 1.3.2-dioxaborolan-2-yl)- 1H-pyrazolc (1.24 g, 6.37 mmol), tert- butyl 3-[(methanesulfonyl)oxy]azetidine-l-carboxylate (1.60 g, 6.37 mmol) and caesium carbonate (3.32 g, 10.2 mmol) in N.N-d i m c th y 1 fo rm am i dc (15 ml) was stirred at 100 C under argon for 14 h. The reaction mixture is mixed with water and filtered. The filtrate was purified directly by HPLC to yield 513 mg (87 % purity, 20 % yield) of the title compound.LC-MS (method 2): Rt= 1.12 min; MS (ESIpos): m/z = 350 [M+H]+-NMR (600 MHz, DMSO-d6) d [ppm]: 1.25 (s, 12H), 1.40 (s, 9H), 4.06 - 4.15 (m, 2H), 4.22 - 4.31 (m, 2H), 5.19 - 5.25 (m, 1H), 7.71 (s, 1H), 8.07 (s, 1H).
  • 2
  • [ 141699-58-3 ]
  • [ 877399-35-4 ]
  • 3
  • [ 141699-58-3 ]
  • [ 1064194-10-0 ]
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 141699-58-3 ]

Amides

Chemical Structure| 132945-75-6

A229347 [132945-75-6]

(S)-tert-Butyl 3-((methylsulfonyl)oxy)pyrrolidine-1-carboxylate

Similarity: 0.89

Chemical Structure| 141699-57-2

A615373 [141699-57-2]

tert-Butyl 3-((methylsulfonyl)oxy)pyrrolidine-1-carboxylate

Similarity: 0.89

Chemical Structure| 129888-60-4

A110474 [129888-60-4]

tert-Butyl 3-((methylsulfonyl)oxy)piperidine-1-carboxylate

Similarity: 0.87

Chemical Structure| 404577-34-0

A457149 [404577-34-0]

(R)-1-N-Boc-3-Methanesulfonyloxypiperidine

Similarity: 0.87

Chemical Structure| 940890-90-4

A878895 [940890-90-4]

(S)-tert-Butyl 3-((methylsulfonyl)oxy)piperidine-1-carboxylate

Similarity: 0.87

Sulfonates

Chemical Structure| 132945-75-6

A229347 [132945-75-6]

(S)-tert-Butyl 3-((methylsulfonyl)oxy)pyrrolidine-1-carboxylate

Similarity: 0.89

Chemical Structure| 141699-57-2

A615373 [141699-57-2]

tert-Butyl 3-((methylsulfonyl)oxy)pyrrolidine-1-carboxylate

Similarity: 0.89

Chemical Structure| 129888-60-4

A110474 [129888-60-4]

tert-Butyl 3-((methylsulfonyl)oxy)piperidine-1-carboxylate

Similarity: 0.87

Chemical Structure| 404577-34-0

A457149 [404577-34-0]

(R)-1-N-Boc-3-Methanesulfonyloxypiperidine

Similarity: 0.87

Chemical Structure| 940890-90-4

A878895 [940890-90-4]

(S)-tert-Butyl 3-((methylsulfonyl)oxy)piperidine-1-carboxylate

Similarity: 0.87

Related Parent Nucleus of
[ 141699-58-3 ]

Azetidines

Chemical Structure| 141699-55-0

A189343 [141699-55-0]

tert-Butyl 3-hydroxyazetidine-1-carboxylate

Similarity: 0.68

Chemical Structure| 429669-07-8

A220489 [429669-07-8]

1-Boc-3-(methoxy)azetidine

Similarity: 0.67

Chemical Structure| 1104083-23-9

A257626 [1104083-23-9]

tert-Butyl 3-hydroxy-3-methylazetidine-1-carboxylate

Similarity: 0.67

Chemical Structure| 147621-21-4

A226506 [147621-21-4]

tert-Butyl azetidine-1-carboxylate

Similarity: 0.63

Chemical Structure| 325775-44-8

A356165 [325775-44-8]

tert-Butyl 3-(aminomethyl)azetidine-1-carboxylate

Similarity: 0.62